Cargando…

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism

Sorafenib is one of the options for advanced hepatocellular carcinoma treatment and has been shown to extend median overall survival. However, sorafenib resistance often develops a few months after treatment. Hence, developing various strategies to overcome sorafenib resistance and understand the po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shueng, Pei-Wei, Chan, Hui-Wen, Lin, Wei-Chan, Kuo, Deng-Yu, Chuang, Hui-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223797/ https://www.ncbi.nlm.nih.gov/pubmed/35742944 http://dx.doi.org/10.3390/ijms23126501

Ejemplares similares

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
por: Chuang, Hui-Yen, et al.
Publicado: (2021)

Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy
por: Hsieh, Chen-Hsi, et al.
Publicado: (2014)

Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model
por: Tyan, Yeu-Sheng, et al.
Publicado: (2021)

Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP
por: Tian, Yu, et al.
Publicado: (2016)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

The Effect of Orlistat on Sterol Metabolism in Obese Patients
por: Kwon, Yu-Jin, et al.
Publicado: (2022)

Cancer Detection Using an Artificial Secretable MicroRNA Found in Blood and Urine
por: Shueng, Pei-Wei, et al.
Publicado: (2022)

Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups
por: Gunay, Yasemin Emur, et al.
Publicado: (2023)

Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
por: Peng, Syue-Wei, et al.
Publicado: (2023)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Resensitizing AMPA receptors
por: Short, Ben
Publicado: (2019)

Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma
por: Hsieh, Chen-Hsi, et al.
Publicado: (2010)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
por: Chen, John Chun-Hao, et al.
Publicado: (2016)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Obesity management: Update on orlistat
por: Drew, Belinda S, et al.
Publicado: (2007)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Osthole resensitizes CD133(+) hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway
por: Ye, Junfeng, et al.
Publicado: (2020)

MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma
por: Bergamini, Christian, et al.
Publicado: (2023)

Resensitization in suspected penicillin allergy
por: Doña, Inmaculada, et al.
Publicado: (2022)

Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
por: Hsieh, Ming-Han, et al.
Publicado: (2020)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Orlistat in the prevention of diabetes in the obese patient
por: Mancini, Marcio C, et al.
Publicado: (2008)

Macrocytic Anemia and Thrombocytopenia Induced by Orlistat
por: Palacios-Martinez, David, et al.
Publicado: (2013)

Acute oxalate nephropathy associated with orlistat
por: Humayun, Youshay, et al.
Publicado: (2016)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma
por: Su, Wen-Lung, et al.
Publicado: (2020)

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
por: Kim, Young-Seon, et al.
Publicado: (2018)

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
por: Musso, Orlando, et al.
Publicado: (2019)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ulmepvrb001sjhib4j13tkrc9